U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drug Shortages

FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages | Contact Us

Start Over | Back to Search Results

Lisdexamfetamine Dimesylate Capsule
Status: Currently in Shortage
»Date first posted: 07/14/2023
»Therapeutic Categories: Psychiatry

Expand all

Alvogen (Revised 04/17/2024)

Company Contact Information:
844-842-8672 and email: CustomerService-US@alvogen.com

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Capsule, 10 mg (NDC 47781-562-01) Limited Availability Shortage of an active ingredient
Capsule, 20 mg (NDC 47781-563-01) Unavailable Shortage of an active ingredient
Capsule, 30 mg (NDC 47781-564-01) Unavailable Shortage of an active ingredient
Capsule, 40 mg (NDC 47781-565-01) Unavailable Resupply End of April 2024 Shortage of an active ingredient
Capsule, 50 mg (NDC 47781-566-01) Unavailable Resupply End of April 2024 Shortage of an active ingredient
Capsule, 60 mg (NDC 47781-567-01) Unavailable DEA Quota Shortage of an active ingredient
Capsule, 70 mg (NDC 47781-568-01) Limited Availability Shortage of an active ingredient

Amneal Pharmaceuticals (Reverified 02/09/2024)

Company Contact Information:
866-525-7270

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Capsule, 20 mg (NDC 65162-023-09) Unavailable Shortage of an active ingredient
Capsule, 30 mg (NDC 65162-024-09) Unavailable Shortage of an active ingredient
Capsule, 40 mg (NDC 65162-025-09) Unavailable Shortage of an active ingredient
Capsule, 50 mg (NDC 65162-026-09) Unavailable Shortage of an active ingredient
Capsule, 60 mg (NDC 65162-027-09) Unavailable Shortage of an active ingredient
Capsule, 70 mg (NDC 65162-028-09) Unavailable Shortage of an active ingredient

Apotex Corp. (Reverified 04/08/2024)

Company Contact Information:
800-706-5575

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Capsule, 10 mg (NDC 60505-4739-1) Unavailable Next resupply to be determined. Shortage of an active ingredient
Capsule, 20 mg (NDC 60505-4740-1) Limited Availability Next resupply to be determined. Shortage of an active ingredient
Capsule, 30 mg (NDC 60505-4741-1) Unavailable Next resupply to be determined. Shortage of an active ingredient
Capsule, 40 mg (NDC 60505-4742-1) Unavailable Next resupply to be determined. Shortage of an active ingredient
Capsule, 50 mg (NDC 60505-4743-1) Limited Availability Next resupply to be determined. Shortage of an active ingredient
Capsule, 60 mg (NDC 60505-4744-1) Limited Availability Next resupply to be determined. Shortage of an active ingredient
Capsule, 70 mg (NDC 60505-4745-1) Limited Availability Next resupply to be determined. Shortage of an active ingredient

Hikma Pharmaceuticals USA, Inc. (Reverified 04/16/2024)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Capsule, 20 mg (NDC 0054-0370-25) Limited Availability Available on allocation Shortage of an active ingredient
Capsule, 30 mg (NDC 0054-0371-25) Limited Availability Available on allocation Shortage of an active ingredient
Capsule, 40 mg (NDC 0054-0372-25) Limited Availability Available on allocation Shortage of an active ingredient
Capsule, 50 mg (NDC 0054-0373-25) Limited Availability Available on allocation Shortage of an active ingredient
Capsule, 60 mg (NDC 0054-0374-25) Limited Availability Available on allocation Shortage of an active ingredient
Capsule, 70 mg (NDC 0054-0375-25) Limited Availability Available on allocation Shortage of an active ingredient

Lannett Company, Inc. (Reverified 04/15/2024)

Company Contact Information:
844-834-0530

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Capsule, 10 mg (NDC 0527-4661-37) Limited Availability Allocating limited inventory Shortage of an active ingredient
Capsule, 20 mg (NDC 0527-4662-37) Unavailable Shortage of an active ingredient
Capsule, 30 mg (NDC 0527-4663-37) Unavailable Shortage of an active ingredient
Capsule, 40 mg (NDC 0527-4664-37) Unavailable Shortage of an active ingredient
Capsule, 50 mg (NDC 0527-4665-37) Unavailable Shortage of an active ingredient
Capsule, 60 mg (NDC 0527-4666-37) Unavailable Shortage of an active ingredient
Capsule, 70 mg (NDC 0527-4667-37) Unavailable Shortage of an active ingredient

Mylan Pharmaceuticals Inc., a Viatris Company (Reverified 04/16/2024)

Company Contact Information:
800-796-9526

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Capsule, 10 mg (NDC 0378-6854-77) Limited Availability Allocating limited inventory Shortage of an active ingredient
Capsule, 20 mg (NDC 0378-6855-77) Limited Availability Allocating limited inventory Shortage of an active ingredient
Capsule, 30 mg (NDC 0378-6856-77) Limited Availability Allocating limited inventory Shortage of an active ingredient
Capsule, 40 mg (NDC 0378-6857-77) Limited Availability Allocating limited inventory Shortage of an active ingredient
Capsule, 50 mg (NDC 0378-6858-77) Limited Availability Allocating limited inventory Shortage of an active ingredient
Capsule, 60 mg (NDC 0378-6859-77) Limited Availability Allocating limited inventory Shortage of an active ingredient
Capsule, 70 mg (NDC 0378-6860-77) Limited Availability Allocating limited inventory Shortage of an active ingredient

Rhodes Pharmaceuticals L.P. (Revised 04/03/2024)

Company Contact Information:
888-827-0616

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Capsule, 10 mg (NDC 42858-161-01) Unavailable Estimated availability: May 2024 Shortage of an active ingredient
Capsule, 20 mg (NDC 42858-162-01) Unavailable Estimated availability: May 2024 Shortage of an active ingredient
Capsule, 30 mg (NDC 42858-163-01) Limited Availability Shortage of an active ingredient
Capsule, 40 mg (NDC 42858-164-01) Limited Availability Shortage of an active ingredient
Capsule, 60 mg (NDC 42858-166-01) Unavailable Estimated availability: May 2024 Shortage of an active ingredient
Capsule, 50 mg (NDC 42858-165-01) Unavailable Estimated availability: May 2024 Shortage of an active ingredient
Capsule, 70 mg (NDC 42858-167-01) Unavailable Estimated availability: May 2024 Shortage of an active ingredient

Solco Healthcare US, LLC (Reverified 04/01/2024)

Company Contact Information:
866-931-9829

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Capsule, 10 mg (NDC 43547-602-10) Limited Availability On allocation Shortage of an active ingredient
Capsule, 20 mg (NDC 43547-603-10) Limited Availability On allocation Shortage of an active ingredient
Capsule, 30 mg (NDC 43547-604-10) Limited Availability On allocation Shortage of an active ingredient
Capsule, 40 mg (NDC 43547-605-10) Limited Availability On allocation Shortage of an active ingredient
Capsule, 50 mg (NDC 43547-606-10) Limited Availability On allocation Shortage of an active ingredient
Capsule, 60 mg (NDC 43547-607-10) Limited Availability On allocation Shortage of an active ingredient
Capsule, 70 mg (NDC 43547-608-10) Limited Availability On allocation Shortage of an active ingredient

SpecGx LLC (Revised 04/03/2024)

Company Contact Information:
800-325-8888

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Capsule, 10 mg (NDC 0406-5111-01) Limited Availability Available for primary customers only; Backorder expected in June with extended backorder once inventory depletes. Shortage of an active ingredient
Capsule, 20 mg (NDC 0406-5112-01) Limited Availability Next release 3/15. Extended backorder expected once inventory depletes, expected in June. Shortage of an active ingredient
Capsule, 30 mg (NDC 0406-5113-01) Limited Availability Next release 3/15. Extended backorder expected once inventory depletes, expected in June. Shortage of an active ingredient
Capsule, 40 mg (NDC 0406-5114-01) Limited Availability Extended backorder expected once inventory depletes, expected in April - Same month as release Shortage of an active ingredient
Capsule, 50 mg (NDC 0406-5115-01) Limited Availability Extended backorder expected once inventory depletes, expected in April - Same month as release Shortage of an active ingredient
Capsule, 60 mg (NDC 0406-5116-01) Limited Availability Next release 3/15. Extended backorder expected once inventory depletes, expected in June. Shortage of an active ingredient
Capsule, 70 mg (NDC 0406-5117-01) Limited Availability Shortage of an active ingredient

Sun Pharmaceutical Industries, Inc. (Revised 03/15/2024)

Company Contact Information:
800-818-4555

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Capsule, 10 mg (NDC 57664-046-88) Unavailable Not available. Return to stock possible in mid of May 2024 Shortage of an active ingredient
Capsule, 30 mg (NDC 57664-048-88) Unavailable Not available. Return to stock possible in mid of May 2024 Shortage of an active ingredient
Capsule, 30 mg (NDC 57664-048-88) Unavailable Not available. Return to stock possible in mid of May 2024 Shortage of an active ingredient
Capsule, 40 mg (NDC 57664-049-88) Unavailable Not available. Return to stock possible in mid of May 2024 Shortage of an active ingredient
Capsule, 50 mg (NDC 57664-050-88) Unavailable Not available. Return to stock possible in mid of May 2024 Shortage of an active ingredient
Capsule, 60 mg (NDC 57664-051-88) Unavailable Not available. Return to stock possible in mid of May 2024 Shortage of an active ingredient
Capsule, 70 mg (NDC 57664-052-88) Unavailable Not available. Return to stock possible in mid of May 2024 Shortage of an active ingredient

Takeda Pharmaceuticals USA Inc. (Reverified 04/15/2024)

Company Contact Information:
877-TAKEDA-7 (1-877-825-3327)

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Vyvanse, Capsule, 10 mg (NDC 59417-101-10) Available
Vyvanse, Capsule, 20 mg (NDC 59417-102-10) Available
Vyvanse, Capsule, 30 mg (NDC 59417-103-10) Available
Vyvanse, Capsule, 40 mg (NDC 59417-104-10) Available
Vyvanse, Capsule, 50 mg (NDC 59417-105-10) Available
Vyvanse, Capsule, 60 mg (NDC 59417-106-10) Available
Vyvanse, Capsule, 70 mg (NDC 59417-107-10) Available
Back to Top